The American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. Through its programs and services, the AACR fosters research in cancer and related biomedical science, accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer, promotes science education and training, and advances the understanding of cancer etiology, prevention, diagnosis and treatment throughout the world.
The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research — from population science and prevention to cancer biology, translational and clinical studies to survivorship and advocacy — and highlights the work of the best minds in research and medicine from institutions all over the world.
The AACR Annual Meeting 2023 is scheduled for April 14-19 at the Orange County Convention Center in Orlando. Check out University of Florida presentations below. UF Health Cancer Center members appear in bold.
Mini-Symposiums
Session MS.IM02.01 | April 17 | 3:07 – 3:22 p.m.
3465 – HDAC8 regulates immune escape in melanoma through increased transcription of inhibitory cytokines that increase accumulation of myeloid-derived suppressor cells (MDSCs)
Chao Zhang, Michael Emmons, Richard Bennett, Jonathan D. Licht, Keiran Smalley
Session MS.MCB06.01 | April 17 | 3:52 – 4:07 p.m.
3484 – Oncohistone H2B-E76K alters gene expression & cellular phenotype in a bronchial epithelial cell line
Kimberly Espinoza Pereira, Richard L. Bennett, Jixiu Shan, Jay Sarthy, Jonathan D. Licht
Session MS.TB05.01 | April 18 | 3:36 – 3:51 p.m.
5777 – Race as a predictive confounder in the rate of transdifferentiation and drug response in human pancreatic acinar ductal metaplasia
Corey Melissa Perkins, Jinmai Jiang, Hesam Hakimjavadi, Jason Brant, Zhongyue Zhang, Ji-Hyun Lee, David Quashie Jr., Yating Mao, Jamel Ali, Sarah Kim, Martha Campbell-Thompson, Thomas Schmittgen
Educational Sessions
Session ED007 | April 15 | 1 – 1:20 p.m.
Bench to bedside and back in cancer cachexia
Andrew Judge
Session ED040 | April 15 | 10:30 – 10:50 a.m.
Sequence-based design of small molecule RNA degraders
Matthew Disney
Poster sessions
Sunday, April 16
Session LBPO.CH01 | 1:30 – 5 p.m.
LB002 / 2 – Extracellular vesicle loading of proteolysis targeting chimeras for targeted therapeutic delivery
Nina Erwin, Xiaoshu Pan, Nikee Awasthee, Yufeng Xiao, Guangrong Zheng, Daiqing Liao, Mei He
Session PO.BCS01.09 | 1:30 – 5 p.m.
870 / 4 – Glutamine metabolism drives some mechanisms of PARP inhibitor persistence in ovarian cancer
Adriana Del Pino Herrera, Meghan Ferrall-Fairbanks, Mehdi Damaghi, Joon-Hyun Song, Snigdha Kanadibhotla
Session PO.CL07.03 | 1:30 – 5 p.m.
904 / 19 – Optimizing CAR T therapy via metabolic engineering for the treatment of glioblastoma
Tanya Ghosh, Avirup Chakraborty, Linchun Jin, Diana Feier, Aryeh Silver, Maryam Rahman, Catherine Flores, Matthew Sarkisian, Jianping Huang, Duane A. Mitchell, Loic P. Deleyrolle
Session PO.ET01.01 | 1:30 – 5 p.m.
551 / 18 – MDM2 inhibition in combination with imipridone ONC201 treatment as a synergistic combination in solid tumors
Andrew George, Ilyas Sahin, Shengliang Zhang, Maximilian Schwermann, Francesca Di Cristofano, Charlotte DeGeorge, Wafik S. El-Deiry
Session PO.ET02.05 | 1:30 – 5 p.m.
571 / 5 – Angiopoietin-like 4 as a potential therapeutic target for clear cell renal carcinoma
Zeng Jin, Umasankar De, Lei Wang, Jeremy Kleberg, Weizhou Zhang, Ryan Kolb
Session PO.MCB09.04 | 1:30 – 5 p.m.
285 / 18 – Dichloroacetate as a novel pharmaceutical treatment for cancer-related fatigue in melanoma
Xinyi Zhang, Won D. Lee, Brooks P. Leitner, Wanling Zhu, Zongyu Li, Rafael C. Gaspar, Alexandra A. Halberstam, Briana Robles, Joshua D. Rabinowitz, Rachel J. Perry
Session PO.PS01.01 | 1:30 – 5 p.m.
740 / 8 – Prevalence and cancer-specific patterns of cannabis use among US cancer survivors, 2016-2021
Chao Cao, Ruixuan Wang, Lin Yang, Electra D. Paskett, Ce Shang
742 / 10 – Trial in progress: Comprehensive outcomes for after cancer health (COACH), a randomized trial assessing health outcomes following primary cancer therapy
Kelly J. Brassil, Alexi Wright, Elizabeth Arthur, Austin Barr, Laura Flora, Barbara Halpenny, Mariah K. Jackson, Jessica Krok-Schoen, Robin Lally, Jennifer Loftis, Debra Lynch Kelly, Leorey Saligan, Rachael Schmidt, Grace L. Smith, Angela Starkweather, Anna Tavormina, Gisele Tlusty, Michael Vazquez, Marilyn Hammer
744 / 12 – Treatment inequities among patients diagnosed with Hodgkin’s lymphoma with and without HIV (2018-2019): an analysis of the US National Cancer Database
Jessica Yasmine Islam, Jennifer McGee, Yi Guo, Marlene Camacho-Rivera, Lubomir Sokol, Susan T. Vadaparampil, Gita Suneja
752/22 Exploring racial and ethnic disparities in pain medication use in patients with colorectal cancer
John M. Allen, MegCholack Awunti, Yi Guo, Sherise C. Rogers, Lisa Scarton, Diana J. Wilkie
Session PO.SHP01.01 | 1:30 – 5 p.m.
714 / 1 – Using empathy-driven instructional design to reimagine cancer research
Janet Brishke, Zachary Jones, Elizabeth A. Shenkman
Session PO.TB05.02 | 1:30 – 5 p.m.
48 / 16 – Increasing the racial diversity of lung adenocarcinoma cell lines
Christopher Leon, Matthew A. Gladstone, Chunli Yan, Diana I. Romero, Yong Huang, Nazarius S. Lamango, Ite A. Offringa
Monday, April 17
Session PO.CL01.03 | 9 a.m. – 12:30 p.m.
2186 / 28 – An exploratory analysis of the intestinal microbiome in neoadjuvant chemotherapy for pancreatic cancer
Sherise C. Rogers, Ryan Thomas, Brain Ramnaraign, Ilyas Sahin, Jesus Fabregas, Karen Russell, Steven Hughes, Ibrahim Nassour, Kathyrn Hitchcock, Omar Kayaleh, Anita Turk, Ji-Hyun Lee, David DeRemer, Carmen Allegra, Thomas George
Session PO.CL01.15 | 9 a.m. – 12:30 p.m.
2315 / 29 – Temporal changes in circulating tumor cells and circulating tumor DNA in patients with resectable pancreatic ductal adenocarcinoma
Yang Zhang, Pablo J. Dopico, Minh-Chau N. Le, Zhijie Yang, Youxiang Wang, Sherise C. Rogers, Thomas J. George, Hugh Z. Fan
Session PO.CL07.12 | 9 a.m. – 12:30 p.m.
2326 / 7 – Proteolysis-targeting chimera against NR4A1 for cancer immunotherapy
Lei Wang, Yufeng Xiao, Rohan P. Master, Zeng Jin, Urvi M. Patel, Yuewan Luo, Daohong Zhou, Guangrong Zheng, Weizhou Zhang
Session PO.ET09.03 | 9 a.m. – 12:30 p.m.
1633 / 23 – ADT-030, a novel dual-acting RAS and β-catenin inhibitor with robust antitumor activity
Veronica Ramirez-Alcantara, Xi Chen, Michele A. Schuler, Dennis Otali, William Grizzle, Kristy Berry, Antonio Ward, Ivan Babic, Elmar Nurmemmedov, Gang Zhou, Chengguo Xing, Greg Gorman, Lori Coward, Yulia Maxuitenko, Adam B. Keeton, Gary A. Piazza
Session PO.ET09.04 | 9 a.m. – 12:30 p.m.
1655 / 12 – Discovery of a novel PP2A activator as a potential therapeutic for FOLFOX resistant colon cancer
Hannah Johnson, Amandeep Singh, Asif Raza, Congzhou M. Sha, Nikolay V. Dokholyan, Satya Narayan, Arun K. Sharma
1657 / 14 – Discovery of a first-in-class multifunctional TYMS non-classical antifolate inhibitors with potent in vivo activity that prolongs survival
Peter Elias Dib, Maria Guijarro, Patrick Kellish, Nick Paciaroni, Akbar Nawab, Jacob Andring, Lidia Kulemina, Derek Leas, Nick Borrero, Carlos Modenutti, Richard Bennett, Jonathan Licht, Robert McKenna, Adrian Roitberg, Frederic Kaye, Maria Zajac-Kaye
Session PO.IM01.08 | 9 a.m. – 12:30 p.m.
1825 / 29 – A bacterial consortium engineered from feces of patients responding to anti-PD1 treatment mediates tumor response through IFNγ in non-small cell lung cancer
Rachel C. Newsome, Joonseok Oh, Wenya Jian, Raad Z. Gharaibeh, Jason Crawford, Christian Jobin
Session PO.MCB07.02 | 9 a.m. – 12:30 p.m.
1478 / 5 – Broad downregulation of normal-specific super-enhancer associated genes in lung adenocarcinoma
Guoshuai Cai, Yihan Liu, Xiang Cui, Christopher Amos, Feifei Xiao
Session PO.PR01.02 | 9 a.m. – 12:30 p.m.
1972 / 13 – Potential predictors of prostate cancer screening: Findings from the MiCaP research digest study
Jessica Otero Machuca, Parisa Fathi, Daniel Lee, Kim Walsh-Childers, Folakemi Odedina
Session PO.PS01.07 | 9 a.m. – 12:30 p.m.
1922 / 28 – PhyloFrame: A machine learning framework for ancestry agnostic disease signatures
Leslie A. Smith, James A. Cahill, Kiley Graim
Session PO.PS01.08 | 9 a.m. – 12:30 p.m.
1932 / 6 – Evaluation of racial and ethnic psychotropic medication use among patients with colorectal cancer
MegCholack Awunti, Yi Guo, Sherise Rogers, Lisa Scarton, Diana Wilkie, John Allen
1935 / 9 – Racial and ethnic disparities in survival among women with advanced-stage ovarian cancer who received systemic therapy: A National Cancer Database analysis
Caretia J. Washington, Shama D. Karanth, Dejana Braithwaite, Tomi F. Akinyemiju
1952 / 26 – Persistent poverty and oral and pharynx cancer incidence and relative survival rates
Shama D. Karanth, Meghann Wheeler, Alex H. Yoon, Caretia J. Washington, Dejana Braithwaite
Session PO.TB02.01 | 9 a.m. – 12:30 p.m.
1215 / 4 – Synthetic colibactins reveal the structural and biological mode-of-action of a microbial carcinogen
Michael W. Dougherty, Rafael Valdés-Mas, Kevin M. Wernke, Raad Z. Gharaibeh, Alberto Riva, Ye Yang, Marcus Muehlbauer, Eran Elinav, Jens Puschhof, Seth B. Herzon, Christian Jobin
Session LBPO.PS01 | 1:30 – 5 p.m.
LB146 / 10 – Imaging surveillance practice patterns among older adults with stage I/II non-small cell lung cancer
Meghann Wheeler, Shama Karanth, Danting Yang, Caretia Washington, Livingstone Aduse-Poku, Hyung-Suk (Alex) Yoon, Jiang Bian, Yi Guo, Dejana Braithwaite
Session PO.CH01.04 | 1:30 – 5 p.m.
3105 / 18 – Design principle of heparanase inhibitors: A combined in vitro and in silico study
Yuzhao Zhang, Meijun Xiong, Zixin Chen, Gustavo Seabra, Jun Liu, Chenglong Li, Lina Cui
Session PO.CL01.08 | 1:30 – 5 p.m.
3301 / 9 – Ultrasensitive compartment-free digital phenotyping of circulating extracellular vesicles for diagnosis of Ewing sarcoma
Yunjie Wen, Vikalp Vishwakarma, Andrew K. Godwin, Yong Zeng
Session PO.CL01.10 | 1:30 – 5 p.m.
3351 / 26 – Identification of novel biomarkers for high grade serous ovarian cancer screening via extracellular vesicle proteomic profiling
Camille V. Trinidad, Harsh B. Pathak, Shibo Cheng, Rashna Madan, Mihaela E. Sardiu, Leonidas E. Bantis, Yong Zeng, Andrew K. Godwin
Session PO.CL13.01 | 1:30 – 5 p.m.
3215 / 8 – Analysis of emergency department patients with known limb bone malignancies
Lauren C. Ladehoff, Kamil Taneja, Karan Patel, Jeeyong Shin, Sahas Chandragiri, Hailey Hsiung, Michael Diaz, Eric M. Toloza
3220 / 13 – Melanoma patients in the emergency department: Characteristics and outcomes
Henna Hundal, Kamil Taneja, Karan Patel, James E. Siegler, Jesse Thon, Jeeyong Shin, Hailey Hsiung, Michael Diaz, Eric M. Toloza
Session PO.ET04.01 | 1:30 – 5 p.m.
2733 / 4 – TYMS as a novel target for AAV-based therapy
Vinod Vijayakurup, Benjamin Meyer, Akbar Nawab, Frederic J. Kaye, Maria V. Guijarro, Maria Zajac-Kaye
Session PO.ET07.01 | 1:30 – 5 p.m.
2804 / 27 – 3D printing of perfusable alveolar model for efficacy evaluation of polyisoprenylated cysteinyl amide inhibitors on lung cancer cells
Diana Isabel Romero, Bing Ren, Christopher Leon, Ite A. Offringa, Nazarius S. Lamango, Yong Huang
Session PO.MCB11.01 | 1:30 – 5 p.m.
2586 / 14 – OncogenicPIK3CA promotes hematopoietic reprogramming and cell transdifferentiation developing hematopoietic malignancy
Emma Kozurek, Erin B. Dickerson, Jong Hyuk Kim
Session PO.MCB11.02 | 1:30 – 5 p.m.
2613 / 16 – Chronic NNAL exposure, mimicking tobacco use in humans, deactivates LKB1 and promotes tumor progression in non-small cell lung cancer
Tengfei Bian, Lingtao Jin, Chengguo Xing
Session PO.PR01.03 | 1:30 – 5 p.m.
3036 / 8 – Associations of total body fat mass and skeletal muscle index with all-cause and cancer-specific mortality in cancer survivors
Livingstone Aduse-Poku, Shama D. Karanth, Meghann Wheeler, Danting Yang, Caretia Washington, Jesus Fabregas, Ting-Yuan David Cheng, Dejana Braithwaite
Session PO.TB03.01 | 1:30 – 5 p.m.
2394 / 16 – Activatable fluorogenic probe for two-photon imaging of heparanase in vivo
Zachary Rabinowitz, Zhishen Wang, Johnathan Somers, Jun Liu, Joyce Jiang, Nina Zhang, Lina Cui
2395 / 17 – A bioluminescent probe for detection and imaging of heparanase enzymatic activity
Johnathan Somers, Kelton Schleyer, Jun Liu, Zhishen Wang, Arjun Kafle, Lina Cui
Session PO.TB04.05 | 1:30 – 5 p.m.
2486 / 26 – Dissecting the lineage specific roles of BCL-XL in breast cancer metastasis
Madison E. Carelock, Mo Jiao, Weizhou Zhang
Session PO.TB11.08 | 1:30 – 5 p.m.
2520 / 28 – Blocking muscle wasting via deletion of the muscle specific E3 ligase, MuRF1, impedes pancreatic tumor growth
Daria Neyroud, Orlando Laitano, Christopher Lopez, David W. Hammers, H Lee Sweeney, Glenn A. Walter, Sarah M. Judge, Andrew R. Judge
Tuesday, April 18
Session LBPO.CL02 | 9 a.m. – 12:30 p.m.
LB203 / 18 – Targeted inhibition of IRAK-4 with CA-4948 (emavusertib) sensitizes metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
Christina A. Von Roemeling, Bently P. Doonan, Rylynn A. Russell, Tyler V. Elliott, Erica Matich, Vincent Archibald, Lan Hoang-Minh, Reinhard W. Von Roemeling, Dora Ferrari, Jamison Hoffman, Duane A. Mitchell
Session PO.BCS01.03 | 9 a.m. – 12:30 p.m.
4286 / 17 – A statistical learning method for simultaneous copy number estimation and subclone clustering with single cell sequencing data
Feifei Xiao, Fei Qin, Guoshuai Cai
Session PO.BCS02.04 | 9 a.m. – 12:30 p.m.
4303 / 1 – High-throughput 3D tumoroid models for immunotherapy and drug discovery
Duy Nguyen, Alexander McGhee, Diego Pedro, Alfonso Pepe, Matthew Schaller, Ryan Smolchek, Jack Famiglietti, Stephanie Warrington, W. Gregory Sawyer
Session PO.CL04.01 | 9 a.m. – 12:30 p.m.
4371 / 14 – iCCaRe: Social determinants of health navigation, psycho-oncology, and emotional support for Black prostate cancer survivors: Review of current practices
Dottington Fullwood, AJ Merriweather, Che Ngufor, Deidre Pereira, KC Balaji, Roxana Dronca, Gerardo Colon-Otero, Jennifer Crook, Parisa Fathi, Emelina Asto-Flores, Shannon Pressey, Folakemi Odedina
4377 / 20 – Economic burden of lung cancer patients in the emergency department
Jayla Hsiung, Kamil Taneja, Bill Hum, Karan Patel, Michael Diaz, Shreyas Chandragiri, Eric M. Toloza
4378 / 21 – Risk factors for death in the emergency department for melanoma patients
Jayla Hsiung, Kamil Taneja, Karan Patel, Michael Diaz, Jared Wolfe, Eric M. Toloza
Session PO.CL07.06 | 9 a.m. – 12:30 p.m.
4451 / 4 – Developing a PROTAC-based NR4A1 degrader for melanoma cancer therapy
Rohan Master, Yuewan Luo, Yufeng Xiao, Daohong Zhou, Lei Wang, Guangrong Zheng, Weizhou Zhang
Session PO.ET06.03 | 9 a.m. – 12:30 p.m.
3929 / 17 – MDMX overexpression in cancer cells confers significant resistance to MDMX inhibitor XI-006 and may modulate chemosensitivity through suppressing p53 activation of pro-apoptotic factors
Andrew George, Arielle De La Cruz, Shengliang Zhang, Ilyas Sahin, Praveen Srinivasan, Maximilian Schwermann, Morgan Turcotte, Taylor Arnoff, Wafik S. El-Deiry
3935 / 23 – CRISPR/Cas9 screens to identify proliferation and resistance mechanisms in uveal melanoma
Richard L. Bennett, Darby Monagle, Katelyn R. Raburn Smith, Amin Sobh, Keiran S. M. Smalley, J William Harbour, Jonathan D. Licht
Session PO.ET06.04 | 9 a.m. – 12:30 p.m.
3952 / 7 – Preclinical anti-tumor effects of MDM4/MDMX inhibitor XI-006 in breast cancer and prostate cancer cell lines mediated through reduced tumor cell migration
Arielle De La Cruz, Andrew George, Payton De La Cruz, Maximilian P. Pinho-Schwermann, Kimberly S. Meza, Taylor Arnoff, Ilyas Sahin, Stephanie L. Graff, Benedito A. Carneiro, Wafik S. El-Deiry
Session PO.IM01.17 | 9 a.m. – 12:30 p.m.
4130 / 19 – Genetically modified hematopoietic stem cells for improvement of immunotherapies against solid malignancies
Laura Falceto Font, Dan Jin, Connor P. Francis, Bayli DiVita Dean, John W. Figg, Brianna McDonald, Catherine Flores
Session PO.MCB10.02 | 9 a.m. – 12:30 p.m.
3794 / 2 – Sensitive detection of microRNA biomarkers of pancreatic cancer using one-pot endonucleolytically exponentiated rolling circle amplification by CRISPR-Cas12a
He Yan, Song Han, Steven Hughes, Yong Zeng
Session PO.PS01.04 | 9 a.m. – 12:30 p.m.
4189 / 18 – Community cancer scientist program: A model for community member advocacy for cancer research
Brooke M. Hensel, Fern J. Webb, Eduardo Ibarra, Carolina Aristizabal, Rosa Barahona, Diana J. Wilkie, Sandra Suther, Lourdes Baezconde-Garbanati, Mariana C. Stern
Session PO.PS01.09 | 9 a.m. – 12:30 p.m.
4216 / 17 – Interactions of greenness with air pollution in relation to postmenopausal breast cancer risk in UK Biobank
Carmen Smotherman, Brian Sprague, Susmita Datta, Dejana Braithwaite, Huaizhen Qin, Lusine Yaghjyan
Session PO.TB04.02 | 9 a.m. – 12:30 p.m.
3606 / 12 – HDAC8-mediated inhibition of EP300 drives a neural crest-like transcriptional state that increases melanoma brain metastasis
Michael Emmons, Alberto Riva, Chao Zhang, Robert Macaulay, Daphne Dupéré-Richér, Bin Fang, John Koomen, Jiannong Li, Ann Chen, Edward Seto, Jonathan Licht, Keiran Smalley
Session PO.CH01.05 | 1:30 – 5 p.m.
5347 / 29 – Selective targeting deacetylase 3 (HDAC3) and HDAC8 by PROTACs
Yufeng Xiao, Seth Hale, Nikee Awasthee, Xuan Zhang, Yi Liu, Zhiguang Huo, Dongwen Lyu, Lei Wang, Weizhou Zhang, Megan Mosteiro, Daiqing Liao, Guangrong Zheng
Session PO.CL01.17 | 1:30 – 5 p.m.
5594 / 18 – Association of circulating cell-free DNA and prostate cancer risk groups in patients undergoing proton therapy
Andrew Bass, Johnny Velasquez, Moein Rajaei, Curtis Bryant, Nancy Mendenhall, Luisel J. Ricks-Santi
Session PO.ET05.02 | 1:30 – 5 p.m.
4879 / 22 – Inhibition of amino acid transporters as a novel mechanism of action of the repurposed anti-cancer agent tranexamic acid
Brian K. Law, Mary E. Law, Amanda F. Ghilardi, Elham Yaaghubi, Brad J. Davis, Zaafir M. Dulloo, Mengxiong Wang, Olga A. Guryanova, Coy D. Heldermon, Stephan C. Jahn, Ronald K. Castellano
Session PO.IM01.16 | 1:30 – 5 p.m.
5114 / 17 – Development of personalized RNA-based immunotherapeutics for glioblastoma
Vrunda Trivedi, Changlin Yang, Oleg Yegorov, Kelena Klippel, Graeme Fenton, Christina Von Roemeling, Lan Hoang-Minh, Elizabeth Ogando-Rivas, Paul Castillo, Kyle Dyson, Ginger Moore, Duane Mitchell
Session PO.MCB06.02 | 1:30 – 5 p.m.
4747 / 10 – NSD2 mutation drives oncogenic programming in mantle cell lymphoma
Jianping Li, Marta Kulis, Alberto Riva, Heidi Casellas Román, Daphne Dupere-Richer, Amin Sobh, Charlotte Leonie Kaestner, Richard L. Bennett, Inaki Martin, Jonathan D. Licht
4761 / 24 – Identifying molecular targets to overcome CNS infiltration in acute lymphoblastic leukemia associated with an activating mutation of the NSD2 histone methyltransferase
Charlotte L. Kaestner, Amin Sobh, Jianping Li, Katelyn Raburn, Alberto Riva, Jason O. Brant, Richard L. Bennett, Jonathan D. Licht
Session PO.MCB09.03 | 1:30 – 5 p.m.
4837 / 10 – Inhibition of mitochondrial fission activates glycogen storage to support cell survival in colon cancer
Sumati Hasani, Lyndsay E. A. Young, Moumita Banerjee, Dylan Rivas, Jinhwan Kim, Ramon Sun, Matthew Gentry, Xiaopeng Xiong, Tianyan Gao
Session PO.TB01.01 | 1:30 – 5 p.m.
4586 / 4 – To define how the uvel melanoma-liver environment crosstalk shapes metastasis growth and therapeutic response
Sathya Neelature Sriramareddy, Zhihua Chen, Jiannong Li, Ann Chen, Jonathan D. Licht, J William Harbour, Keiran Smalley
Session PO.TB11.09 | 1:30 – 5 p.m.
4611 / 1 – Leveraging organotypic brain slice models to enhance adoptive cellular therapies
Alexandra Reid, Dan Jin, Bayli DiVita-Dean, Laura Falceto-Font, John Figg, Connor Francis, Catherine Flores
Wednesday, April 19
Session PO.BCS01.07 | 9 a.m. – 12:30 p.m.
6537 / 3 – Single cell transcriptomics uncovers cellular and molecular differences in PBMCs of responders and non-responders to the MUC1 cancer vaccine given in the preventative setting
Daniel Y. Yuan, Michelle L. McKeague, Matthew T. Dracz, Olivera J. Finn, Panayiotis V. Benos
Session PO.CL01.18 | 9 a.m. – 12:30 p.m.
6707 / 27 – Optimization of miRNA isolation from plasma biopsies of proton therapy prostate cancer patients
Johnny I. Velasquez, Andrew Bass, Moein Rajaei, Curtis Bryant, Nancy Mendenhall, Luisel Ricks-Santi
Session PO.ET06.05 | 9 a.m. – 12:30 p.m.
6148 / 10 – Disulfide isomerases AGR2, ERp44, and PDIA1 maintain death receptor 5 in an auto-inhibited, monomeric form
Brian K. Law, Mary E. Law, Elham Yaaghubi, Amanda Ghilardi, Brad J. Davis, Renan Ferreira, Samantha Eggleston, Jade Nguyen, Grace Alexandrow, Jin Koh, Sixue Chen, Chi-Wu Chiang, Coy Heldermon, Peter Norgaard, Ronald K. Castallano, Zaafir M. Dulloo
6161 / 23 – Targeting endogenous and therapy-induced dependence on BCL-XL in high grade serous ovarian carcinoma
Lissah Johnson, Xingping Qin, Cameron Fraser, Elizabeth Stover, Yang Yang, Daohong Zhou, Bo Rueda, Kristopher Sarosiek
Session PO.ET09.09 | 9 a.m. – 12:30 p.m.
6248 / 18 – Inhibiting β-catenin in AML by targeting DDX5
WEI NI, Swati Garg, Fen Zhu, Ellen L. Weisberg, Basudev Chowdhury, Martin Sattler, Amulya Jakkani, Suiyang Liu, Dana M. Sanchez, Lizi Wu, Richard M. Stone, Matthew S. Davids, James D. Griffin
Session PO.PS01.06 | 9 a.m. – 12:30 p.m.
6454 / 8 – Metabolic obesity phenotype and risk of obesity-related cancers in the women’s health initiative
Prasoona Karra, Maci Winn, Garnet Anderson, Benjamin Haaland, Aladdin H. Shadyab, Marian Neuhouser, Rebecca Seguin-Fowler, Cynthia A. Thomson, Mace Coday, Jean Wactawski-Wende, Marcia L. Stefanick, Xiaochen Zhang, Ting-Yuan David Cheng, Shama Karanth, Yangbo Sun, Nazmus Saquib, Margaret Pichado, Su Yon Jung, Fred Tabung, Scott A. Summers, William L. Holland, Thunder Jalili, Marc Gunter, Sheetal Hardikar, Mary C. Playdon
Session PO.TB11.10 | 9 a.m. – 12:30 p.m.
5961 / 22 – Inhibition of AURKA destabilizes glioblastoma primary cilia and sensitizes cells to tumor treating fields (TTFields) in vitro and ex vivo
Jia Tian, Julianne Mallinger, Ping Shi, Dahao Ling, Loic Deleyrolle, Min Lin, Habibeh Khoshbouei, Matthew Sarkisian
Florida-California Cancer Research, Education and Engagement (CaRE2) Health Equity Center
CaRE2 is a bicoastal cancer research and training center that brings together Florida A&M University, the University of Florida Health Cancer Center and the University of Southern California Norris Comprehensive Cancer Center. The CaRE2 Health Equity Center is funded by grants from the National Cancer Institute, Center for Reducing Cancer Health Disparities, U54 CA233396, U54 CA233444 and U54 233465.
Sunday, April 16
Session PO.PS01.01 | 1:30 – 5 p.m.
752/22 Exploring racial and ethnic disparities in pain medication use in patients with colorectal cancer
John M. Allen, MegCholack Awunti, Yi Guo, Sherise C. Rogers, Lisa Scarton, Diana J. Wilkie
Session PO.CH01.01 | 1:30 – 5 p.m.
816 / 6 – Biological evaluation of novel stearoyl gemcitabine nanoparticles in primary pancreatic cancer cells and PDX mice tumor models
Esther K. Frimpong, Andriana Inkoom, Nkafu B. Ndemazie, Raviteja Bulusu, Joy C. Okoro, Bo Han, Jose Trevino, Edward Agyare
Session PO.TB05.02 | 1:30 – 5 p.m.
48 / 16 – Increasing the racial diversity of lung adenocarcinoma cell lines
Christopher Leon, Matthew A. Gladstone, Chunli Yan, Diana I. Romero, Yong Huang, Nazarius S. Lamango, Ite A. Offringa
Session PO.TB05.03 | 1:30 – 5 p.m.
5 / 5 – Alveolar epithelial type 1 cells can serve as a cell of origin for lung adenocarcinoma with distinct molecular and phenotypic presentation
Minxiao Yang, Hua Shen, Per Flodby, Michael Koss, Rania Bassiouni, Yixin Liu, Theresa Ryan Stueve, Daniel J. Mullen, Amy L. Ryan, Tea Jashashvili, John Carpten, Alessandra Castaldi, W. Dean Wallace, Beiyun Zhou, Zea Borok, Crystal N. Marconett
Session PO.CH01.01 | 1:30 – 5 p.m.
839 / 29 – Characterization and evaluation of modified 5-fluorouracil loaded liposomal nanoparticle on pancreatic and colorectal cancer cell lines
Raviteja Bulusu, Nkafu B. Ndemazie, Esther K. Frimpong, Andriana Inkoom, Joy C. Okoro, Xue Y. Zhu
Monday, April 17
Session PO.PS01.08 | 9 a.m. – 12:30 p.m.
1932 / 6 – Evaluation of racial and ethnic psychotropic medication use among patients with colorectal cancer
MegCholack Awunti, Yi Guo, Sherise Rogers, Lisa Scarton, Diana Wilkie, John Allen
Session PO.ET07.01 | 1:30 – 5 p.m.
2804 / 27 – 3D printing of perfusable alveolar model for efficacy evaluation of polyisoprenylated cysteinyl amide inhibitors on lung cancer cells
Diana Isabel Romero, Bing Ren, Christopher Leon, Ite A. Offringa, Nazarius S. Lamango, Yong Huang
Session PO.CH01.04 | 1:30 – 5 p.m.
3102 / 15 – Synthesis of N-benzoylamino-tetrahydropyridine analogues as selective COX-2 inhibitors and anti-breast cancer agents
Shasline Gedeon, Madhavi Gangapuram, Kinfe K. Redda, Tiffany Ardley
Session PO.CL01.03 | 9 a.m. – 12:30 p.m.
2186 / 28 – An exploratory analysis of the intestinal microbiome in neoadjuvant chemotherapy for pancreatic cancer
Sherise C. Rogers, Ryan Thomas, Brain Ramnaraign, Ilyas Sahin, Jesus Fabregas, Karen Russell, Steven Hughes, Ibrahim Nassour, Kathyrn Hitchcock, Omar Kayaleh, Anita Turk, Ji-Hyun Lee, David DeRemer, Carmen Allegra, Thomas George
Session PO.PS01.07 | 9 a.m. – 12:30 p.m.
1910 / 16 – Patient race and ethnicity, experiences with care, and guideline concordant treatment for colorectal cancer among those with multimorbidity
Stephanie Navarro, Jennifer Tsui, Afsaneh Barzi, Mariana Stern, Trevor Pickering, Albert Farias
Tuesday, April 18
Session PO.PS01.04 | 9 a.m. – 12:30 p.m.
4189 / 18 – Community cancer scientist program: A model for community member advocacy for cancer research
Brooke M. Hensel, Fern J. Webb, Eduardo Ibarra, Carolina Aristizabal, Rosa Barahona, Diana J. Wilkie, Sandra Suther, Lourdes Baezconde-Garbanati, Mariana C. Stern
Session MS.TB05.01 | 3:36 – 3:51 p.m.
5777 – Race as a predictive confounder in the rate of transdifferentiation and drug response in human pancreatic acinar ductal metaplasia
Corey Melissa Perkins, Jinmai Jiang, Hesam Hakimjavadi, Jason Brant, Zhongyue Zhang, Ji-Hyun Lee, David Quashie Jr., Yating Mao, Jamel Ali, Sarah Kim, Martha Campbell-Thompson, Thomas Schmittgen
PO.PS01.02 | 1:30 – 5 p.m.
5217 / 4 – Genome-wide interactions of processed and red meat intake on colorectal cancer risk
Joel Sanchez Mendez, Mariana C. Stern, Andre Kim, John Morrison, Juan P. Lewinger, Li Hsu, Eric Kawaguchi, Ulrike Peters, William J. Gauderman, on behalf of GECCO, CCFR and CORECT
Session PO.MD01.01 | 9 a.m. – 12:30 p.m.
4266 / 15 – Genomic landscape of prostate cancer: Bioinformatic analysis of TCGA PanCancer data by race and identification of key pathways and genes in PTEN mutation
Olumide Arigbede, Sarah G. Buxbaum, Sara Falzarano, Suhn K. Rhie
Session PO.IM01.17 | 9 a.m. – 12:30 p.m.
4112 / 1 – Evaluating the survival outcomes of an anti-isoaspELAVL4 response in a small cell lung cancer mouse model
Diego A. Velarde, Sarah A. Elmalh, Hannah Lee, Joseph Valdes, Matthew Gladstone, Ryan E. Dinigle, Martin Kast, Ite A. Offringa
Session PO.CL01.17 | 1:30 – 5 p.m.
5594 / 18 – Association of circulating cell-free DNA and prostate cancer risk groups in patients undergoing proton therapy
Andrew Bass, Johnny Velasquez, Moein Rajaei, Curtis Bryant, Nancy Mendenhall, Luisel J. Ricks-Santi
Wednesday, April 19
Session PO.CL01.18 | 9 a.m. – 12:30 p.m.
6707 / 27 – Optimization of miRNA isolation from plasma biopsies of proton therapy prostate cancer patients
Johnny I. Velasquez, Andrew Bass, Moein Rajaei, Curtis Bryant, Nancy Mendenhall, Luisel Ricks-Santi
